The first neighbors of NR1I2 (target of Paxlovid) are linked with colorectal carcinoma, obesity, Fanconi renotubular syndrome with maturity-onset diabetes of the young, thrombocytopenia, and cardiomyopathy. Here, NR1I2 is linked to colorectal carcinoma.